IN2014DN08451A - - Google Patents
Info
- Publication number
- IN2014DN08451A IN2014DN08451A IN8451DEN2014A IN2014DN08451A IN 2014DN08451 A IN2014DN08451 A IN 2014DN08451A IN 8451DEN2014 A IN8451DEN2014 A IN 8451DEN2014A IN 2014DN08451 A IN2014DN08451 A IN 2014DN08451A
- Authority
- IN
- India
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6596—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having atoms other than oxygen, sulfur, selenium, tellurium, nitrogen or phosphorus as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/331—Universal or degenerate base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613385P | 2012-03-20 | 2012-03-20 | |
| PCT/US2013/029684 WO2013142087A1 (en) | 2012-03-20 | 2013-03-07 | Boronic acid conjugates of oligonucleotide analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08451A true IN2014DN08451A (en) | 2015-05-08 |
Family
ID=49223176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8451DEN2014 IN2014DN08451A (en) | 2012-03-20 | 2014-10-09 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9920085B2 (en) |
| EP (1) | EP2828395B1 (en) |
| JP (1) | JP6542662B2 (en) |
| KR (1) | KR102079284B1 (en) |
| CN (1) | CN104411831B (en) |
| AU (3) | AU2013235691B2 (en) |
| BR (1) | BR112014023347A2 (en) |
| CA (1) | CA2868174A1 (en) |
| EA (1) | EA031110B1 (en) |
| ES (1) | ES2706198T3 (en) |
| HK (1) | HK1206064A1 (en) |
| IN (1) | IN2014DN08451A (en) |
| MX (1) | MX358497B (en) |
| NZ (1) | NZ700399A (en) |
| WO (1) | WO2013142087A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2361325T3 (en) | 2004-06-28 | 2011-06-16 | The University Of Western Australia | OLIGONUCLEÓTIDOS ANTISENTIDO TO INDUCE THE OMISSION OF EXON AND METHODS OF USE OF THE SAME. |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| EP3431603A1 (en) | 2009-11-12 | 2019-01-23 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
| KR102095478B1 (en) | 2010-05-28 | 2020-04-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| CN111808135A (en) | 2011-11-18 | 2020-10-23 | 萨勒普塔医疗公司 | Functionally modified oligonucleotides and subunits thereof |
| IL280443B (en) * | 2013-03-14 | 2022-07-01 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| ES2714290T3 (en) * | 2013-03-14 | 2019-05-28 | Sarepta Therapeutics Inc | Exon skipping compositions for the treatment of muscular dystrophy |
| EA201591792A1 (en) | 2013-03-15 | 2016-02-29 | Сарепта Терапьютикс, Инк. | IMPROVED COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DISTROPHIA |
| NZ737757A (en) * | 2015-05-19 | 2023-07-28 | Sarepta Therapeutics Inc | Peptide oligonucleotide conjugates |
| WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| CA2996164A1 (en) | 2015-08-28 | 2017-03-09 | Sarepta Therapeutics, Inc. | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
| CN108291225B (en) * | 2015-10-05 | 2022-07-12 | ProQR治疗上市公司Ⅱ | Use of single-stranded antisense oligonucleotides for preventing or treating genetic diseases involving repeated amplification of trinucleotide |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| DE3650699T2 (en) | 1985-03-15 | 1999-04-15 | Antivirals Inc | Immunoassay for polynucleotide and methods |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| DE69034213T2 (en) | 1989-12-20 | 2006-08-24 | Avi Biopharma, Inc., Portland | UNLOADED MORPHOLIN-BASED POLYMERS WITH CHIRAL, PHOSPHOROUS BRIDGES BETWEEN THE SUB-UNITS |
| WO1993001286A2 (en) | 1991-06-28 | 1993-01-21 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| US6030954A (en) | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| CA2252706A1 (en) | 1996-05-01 | 1997-11-06 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
| DE19716073A1 (en) | 1997-04-17 | 1998-10-22 | Boehringer Mannheim Gmbh | Dosing device for dispensing small amounts of liquid |
| US6548651B1 (en) | 1998-11-11 | 2003-04-15 | Pantheco A/S | Modified peptide nucleic acid (PNA) molecules |
| ATE301664T1 (en) * | 1999-03-19 | 2005-08-15 | Agilent Technologies Inc | REAGENTS AND OLIGONUCLEOTIDES CONTAINING BORONIC ACID |
| WO2001049775A2 (en) | 2000-01-04 | 2001-07-12 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
| ATE356231T1 (en) * | 2000-01-11 | 2007-03-15 | Nanogen Recognomics Gmbh | BIOMOLECULES WITH MULTIPLE BONDING SECTIONS FOR BONDING TO A SUBSTRATE SURFACE |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| EP1296718A1 (en) | 2000-04-06 | 2003-04-02 | Pantheco A/S | Pharmaceutical composition of modified pna molecules |
| EP2277894A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
| WO2002079467A2 (en) | 2001-03-29 | 2002-10-10 | Københavns Universitet | Antibiotic-free bacterial strain selection with antisense molecules |
| AU2002317437A1 (en) | 2001-05-18 | 2002-12-03 | Cureon A/S | Therapeutic uses of lna-modified oligonucleotides in infectious diseases |
| US7620500B2 (en) | 2002-03-09 | 2009-11-17 | Maxygen, Inc. | Optimization of crossover points for directed evolution |
| AU2003280247A1 (en) | 2002-11-05 | 2004-06-07 | Affinium Pharmaceuticals, Inc. | Essential novel bacterial polypeptides |
| DE602004028930D1 (en) | 2003-04-29 | 2010-10-14 | Avi Biopharma Inc | COMPOSITIONS FOR IMPROVING ANTISENSE EFFECTIVENESS AND TRANSPORT OF NUCLEIC ACID ANALOGUE IN CELLS |
| NZ543653A (en) | 2003-05-23 | 2008-10-31 | Epfl Ecole Polytechnique Federale Lausanne | Methods for protein labeling based on acyl carrier protein |
| US7402574B2 (en) | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
| ES2361325T3 (en) | 2004-06-28 | 2011-06-16 | The University Of Western Australia | OLIGONUCLEÓTIDOS ANTISENTIDO TO INDUCE THE OMISSION OF EXON AND METHODS OF USE OF THE SAME. |
| CA2875436A1 (en) | 2004-07-02 | 2006-08-17 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| GB0501944D0 (en) * | 2005-01-31 | 2005-03-09 | Univ Cambridge Tech | Compounds for use in chemical detection and/or quantitation |
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US20060293268A1 (en) | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US7790694B2 (en) | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| EP2024499B1 (en) | 2006-05-10 | 2017-10-25 | Sarepta Therapeutics, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
| WO2008018795A1 (en) | 2006-08-11 | 2008-02-14 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| US20100190689A1 (en) | 2006-09-21 | 2010-07-29 | University Of Rochester | Compositions and methods related to protein displacement therapy for myotonic distrophy |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| JP5512533B2 (en) | 2007-11-15 | 2014-06-04 | サレプタ セラピューティクス， インコーポレイテッド | Method for synthesizing morpholino oligomers |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| EP2310054A4 (en) * | 2008-08-15 | 2013-01-09 | Univ Georgia State Res Found | Aptamer inhibition of thrombus formation |
| EP4174178A1 (en) | 2008-10-24 | 2023-05-03 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| KR102095478B1 (en) | 2010-05-28 | 2020-04-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| JP5831455B2 (en) | 2010-09-30 | 2015-12-09 | 日本新薬株式会社 | Morpholino nucleic acid derivatives |
| US9061960B2 (en) | 2012-05-30 | 2015-06-23 | Basf Se | Method for working up mixtures |
-
2013
- 2013-03-07 US US14/386,720 patent/US9920085B2/en active Active
- 2013-03-07 JP JP2015501712A patent/JP6542662B2/en active Active
- 2013-03-07 AU AU2013235691A patent/AU2013235691B2/en not_active Ceased
- 2013-03-07 EA EA201491726A patent/EA031110B1/en unknown
- 2013-03-07 ES ES13765016T patent/ES2706198T3/en active Active
- 2013-03-07 MX MX2014011276A patent/MX358497B/en active IP Right Grant
- 2013-03-07 NZ NZ700399A patent/NZ700399A/en not_active IP Right Cessation
- 2013-03-07 CN CN201380023605.6A patent/CN104411831B/en not_active Expired - Fee Related
- 2013-03-07 BR BR112014023347A patent/BR112014023347A2/en active Search and Examination
- 2013-03-07 WO PCT/US2013/029684 patent/WO2013142087A1/en active Application Filing
- 2013-03-07 EP EP13765016.4A patent/EP2828395B1/en active Active
- 2013-03-07 KR KR1020147029235A patent/KR102079284B1/en active IP Right Grant
- 2013-03-07 CA CA2868174A patent/CA2868174A1/en not_active Abandoned
-
2014
- 2014-10-09 IN IN8451DEN2014 patent/IN2014DN08451A/en unknown
-
2015
- 2015-07-07 HK HK15106455.8A patent/HK1206064A1/en not_active IP Right Cessation
-
2017
- 2017-05-01 AU AU2017202883A patent/AU2017202883A1/en not_active Abandoned
-
2019
- 2019-03-22 AU AU2019201989A patent/AU2019201989A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102079284B1 (en) | 2020-02-19 |
| US9920085B2 (en) | 2018-03-20 |
| US20150080340A1 (en) | 2015-03-19 |
| MX2014011276A (en) | 2014-10-06 |
| NZ700399A (en) | 2016-07-29 |
| MX358497B (en) | 2018-08-23 |
| WO2013142087A1 (en) | 2013-09-26 |
| AU2013235691B2 (en) | 2017-02-02 |
| HK1206064A1 (en) | 2015-12-31 |
| JP2015512254A (en) | 2015-04-27 |
| EP2828395A4 (en) | 2015-11-18 |
| CA2868174A1 (en) | 2013-09-26 |
| EA031110B1 (en) | 2018-11-30 |
| KR20140138995A (en) | 2014-12-04 |
| CN104411831A (en) | 2015-03-11 |
| EP2828395A1 (en) | 2015-01-28 |
| BR112014023347A2 (en) | 2017-07-18 |
| AU2013235691A1 (en) | 2014-10-16 |
| ES2706198T3 (en) | 2019-03-27 |
| CN104411831B (en) | 2020-08-11 |
| EA201491726A1 (en) | 2015-03-31 |
| AU2017202883A1 (en) | 2017-05-18 |
| EP2828395B1 (en) | 2018-10-24 |
| AU2019201989A1 (en) | 2019-04-11 |
| JP6542662B2 (en) | 2019-07-10 |